Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL

Enrollment

226

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

February 28, 2005

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

adalimumab

80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29

BIOLOGICAL

placebo

2 injections Day 1, 1 injection Days 15 and 29

BIOLOGICAL

adalimumab

40 mg adalimumab every other week